ERBB2 and breast carcinoma: The phospho-proteins in the PI3K/mTORC1 pathway, including p-mTOR (S2448), p-AKT (S473), and p-RPS6 (S235/236), have been tested in response to trastuzumab in both sensitive and resistant HER2+ breast cancer cells [360].